PARLIAMENTARY EARLY DAY MOTION
TREATMENT FOR KIDNEY CANCER (12 July 2010)

That this House observes that between 7,000 and 8,000 people are diagnosed with kidney cancer in the UK each year, and that around 40 per cent. of patients have advanced cancer at the time of diagnosis; notes that everolimus is the only licensed treatment for patients with advanced and/or metastatic renal cell carcinoma who have failed on first-line treatment; notes with concern that the National Institute for Health and Clinical Excellence (NICE) has not recommended funding for everolimus; is concerned by the number of clinically effective cancer drugs which are turned down by NICE despite additional guidance on end-of-life medicines issued by NICE to the appraisal committees; and calls on NICE to reconsider its recommendations so that patients may be able to access this drug on the NHS.

Sponsored by:
Mrs Sharon Hodgson (Labour)